Abcuro

Drug Discovery · Newton, MA · Founded 2015 · Privately Held (backing)

Developer of immunomodulatory therapeutics designed for treating both autoimmunity and cancer. Abcuro is based in Newton, MA and was founded in 2015. It was valued at $700 million at its later-stage round in Feb 2025, the last priced event on record. It has raised $407 million across 5 recorded rounds; the latest was a $200 million Series C in Feb 2025.

PMV mark · valuation
$700.0M
Oct 2026
Priced at
its later-stage round
Feb 2025
Total raised
$407.3M
Last round
Later Stage VC (Series C)
Feb 2025
What is Abcuro worth?
$700.0MPrivateMarketView mark · Oct 2026

Valued at $700.0M at its later-stage round, Feb 2025. Nothing has traded since.

Free account
More of Abcuro with a free account
  • ·The complete investor list: 20 names
  • ·Watch Abcuro: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Valuation timeline

0 priced rounds · 32 daily marks since · Sep 2026 – Oct 2026
▮▮
Markrounds hold their value until the next priced eventMark, today
log scale
Post-money values unlock with a free account.Unlock the axis

Membership and data by Private Market View

Abcuro funding history

5 rounds
DateRoundRaisedPost-money
Feb 2025Later Stage VC (Series C)$200.0M▮
Aug 2023Later Stage VC (Series B)$155.0M▮
Jun 2020Early Stage VC$15.5M▮
Nov 2018Early Stage VC$8.0M▮
Nov 2016Seed Round$2.3M▮
Unlock post-money valuations

Membership and data by Private Market View

Abcuro valuation

Abcuro was valued at $700 million at its later-stage round in Feb 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has Abcuro raised?

Abcuro has raised $407 million across 5 recorded rounds since 2016. The largest was an $8 million early-stage round in Nov 2018; the most recent was a $200 million Series C in Feb 2025.

Abcuro has filed 6 Form Ds with the SEC since 2016, most recently in Feb 2025 ($80 million sold to 21 investors).

Comparable companies

Comparable drug discovery names by valuation on PrivateMarketView: Bluejay Therapeutics ($820 million), Candid Therapeutics ($657 million) and Kardigan ($646 million).

How Abcuro's valuation is determined

Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.

For Abcuro, the most current credible signal sets the number and the older ones confirm it: a live secondary-market price first, then three or more recent prints, then institutional fund marks, and otherwise the last priced round, which never decays. The valuation is the last round’s post-money moved by the price change since that round, so no share count is assumed. Today it is set by its last priced round. Question about this number? Full methodology →

Frequently asked about Abcuro

What is Abcuro worth?
Abcuro is valued at $700.0M as of Oct 2026. Valued at $700.0M at its later-stage round, Feb 2025. Nothing has traded since.
How much has Abcuro raised?
Abcuro has raised $407.3M in total funding across 5 recorded rounds.
When did Abcuro last raise?
Abcuro last raised in Feb 2025 (Later Stage VC (Series C)), raising $200.0M.